| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fabrício A Moreira, Antônio C P de Oliveira, Victor R Santos, Márcio F D Morae. Cannabidiol and epilepsy. International review of neurobiology. vol 177. 2024-07-19. PMID:39029983. |
cannabidiol and epilepsy. |
2024-07-19 |
2024-07-22 |
Not clear |
| Rayssa C Briânis, Fabrício A Moreira, Lia P Iglesia. Cannabidiol and addiction. International review of neurobiology. vol 177. 2024-07-19. PMID:39029990. |
cannabidiol (cbd) has been investigated for several therapeutic applications, having reached the clinics for the treatment of certain types of epilepsies. |
2024-07-19 |
2024-07-22 |
Not clear |
| Xin Wang, Haiyan Zhu, Tao Liu, Zhi Guo, Chenyang Zhao, Zhiyi He, Wenxu Zhen. Comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis. Frontiers in neurology. vol 15. 2024-07-12. PMID:38994494. |
comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis. |
2024-07-12 |
2024-07-14 |
Not clear |
| Xin Wang, Haiyan Zhu, Tao Liu, Zhi Guo, Chenyang Zhao, Zhiyi He, Wenxu Zhen. Comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis. Frontiers in neurology. vol 15. 2024-07-12. PMID:38994494. |
to evaluate the comparative efficacy and safety of various doses of oral cannabidiol (cbd) in treating refractory epilepsy indications, thus providing more informative evidence for clinical decision-making. |
2024-07-12 |
2024-07-14 |
Not clear |
| Virginia Brighenti, Matilde Marani, Clarissa Caroli, Laura Bertarini, Alessio Gaggiotti, Federica Pollastro, Caterina Durante, Giuseppe Cannazza, Federica Pellat. A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. Analytical and bioanalytical chemistry. 2024-06-28. PMID:38940871. |
cannabidiol (cbd) is the main non-psychoactive phytocannabinoid derived from cannabis sativa l. it is now an active pharmaceutical ingredient (api), given its usage in treating some types of pediatric epilepsy. |
2024-06-28 |
2024-06-30 |
Not clear |
| Ivan Santos, M Beatriz P P Oliveira, Ana Casas, Javier Fidalgo, Hugo Almeid. Understanding the Potential of CBD for Health Benefits: an Overview. Current drug discovery technologies. 2024-06-07. PMID:38847170. |
cannabidiol (cbd) is a well-known cannabinoid with potential benefits, including reducing epilepsy seizures, alleviating anxiety, and obsessive-compulsive disorder (ocd) symptoms, aiding in tourette syndrome (a neurodevelopmental disorder), depression, sleep disorders, and promising in the treatment of cancer, pain relief, and heart health. |
2024-06-07 |
2024-06-10 |
Not clear |
| Samuel Fernando Vargas Chico, Daniel Alejandro Melendez Diaz, Neyder Contreras-Puente. Use of cannabidiol in the treatment of drug-refractory epilepsy in children and young adults: A systematic review. Journal of neurosciences in rural practice. vol 15. issue 2. 2024-05-16. PMID:38746511. |
use of cannabidiol in the treatment of drug-refractory epilepsy in children and young adults: a systematic review. |
2024-05-16 |
2024-05-27 |
Not clear |
| Maria Concetta Rotolo, Silvia Graziano, Adele Minutillo, Maria Rosaria Varì, Simona Pichini, Emilia Marche. OILVEQ: an Italian external quality control scheme for cannabinoids analysis in galenic preparations of cannabis oil. Clinical chemistry and laboratory medicine. 2024-05-10. PMID:38727000. |
italy legalized cannabis oil for specific medical conditions (neuropathic pain, refractory epilepsy and other established pathologies) in 2015, but mandates titration of principal cannabinoids before marketing each batch using iphenated techniques coupled with mass spectrometry. |
2024-05-10 |
2024-05-27 |
Not clear |
| Federica Pigliasco, Alessia Cafaro, Sebastiano Barco, Manuela Stella, Francesca Mattioli, Antonella Riva, Maria Margherita Mancardi, Simona Lattanzi, Roberto Bandettini, Pasquale Striano, Giuliana Cangem. Innovative LC-MS/MS method for therapeutic drug monitoring of fenfluramine and cannabidiol in the plasma of pediatric patients with epilepsy. Journal of pharmaceutical and biomedical analysis. vol 245. 2024-05-04. PMID:38703746. |
innovative lc-ms/ms method for therapeutic drug monitoring of fenfluramine and cannabidiol in the plasma of pediatric patients with epilepsy. |
2024-05-04 |
2024-05-07 |
human |
| Barbara A Brett, Matthieu Conroy, Hardik Doshi, Matthew X Lowe, Sasha Kalcheff-Korn, Heather Jackso. An observational time-series study on the behavioral effects of adjunctive artisanal cannabidiol use by adults with treatment resistant epilepsies. BMC neurology. vol 24. issue 1. 2024-04-27. PMID:38671370. |
an observational time-series study on the behavioral effects of adjunctive artisanal cannabidiol use by adults with treatment resistant epilepsies. |
2024-04-27 |
2024-04-29 |
Not clear |
| Dawid M Zakrzewski, Patrycja Podlejska, Wiktoria Kubziakowska, Kamil Dzwilewski, Przemysław M Waszak, Marta Zawadzka, Maria Mazurkiewicz-Bełdzińsk. Evaluating the Credibility and Reliability of Online Information on Cannabidiol (CBD) for Epilepsy Treatment in Poland. Healthcare (Basel, Switzerland). vol 12. issue 8. 2024-04-26. PMID:38667591. |
evaluating the credibility and reliability of online information on cannabidiol (cbd) for epilepsy treatment in poland. |
2024-04-26 |
2024-04-28 |
Not clear |
| Dawid M Zakrzewski, Patrycja Podlejska, Wiktoria Kubziakowska, Kamil Dzwilewski, Przemysław M Waszak, Marta Zawadzka, Maria Mazurkiewicz-Bełdzińsk. Evaluating the Credibility and Reliability of Online Information on Cannabidiol (CBD) for Epilepsy Treatment in Poland. Healthcare (Basel, Switzerland). vol 12. issue 8. 2024-04-26. PMID:38667591. |
the aim of our work was to evaluate the information contained on the websites, including social media, in terms of the credibility and the reliability of current knowledge about the usage of products containing cannabidiol in epilepsy treatment. |
2024-04-26 |
2024-04-28 |
Not clear |
| Correction to "Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program". Epilepsia. 2024-04-04. PMID:38572913. |
correction to "efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the expanded access program". |
2024-04-04 |
2024-04-06 |
Not clear |
| Mohamed Osman, Jamileh Khalil, Mostafa El-Bahri, Jamal Swalah Mcdahrou, Reem Fahda, Reymin Mustafa, Arthur Ooi, Marwa Attayee, Rachelle Catanzariti, Lisa Pont, Kylie Williams, Stewart Yeung, Kamal Dua, Gabriele De Rubis, Raimar Loebenber. Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations. Chemico-biological interactions. 2024-04-04. PMID:38574834. |
decoding epilepsy treatment: a comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations. |
2024-04-04 |
2024-04-07 |
Not clear |
| Yasaman Javadzadeh, Alexandra Santos, Mark S Aquilino, Shanthini Mylvaganam, Karolina Urban, Peter L Carle. Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ Cells. vol 13. issue 6. 2024-03-27. PMID:38534310. |
cannabidiol exerts anticonvulsant effects alone and in combination with Δ cannabinoids have shown potential in drug-resistant epilepsy treatment; however, we lack knowledge on which cannabinoid(s) to use, dosing, and their pharmacological targets. |
2024-03-27 |
2024-03-29 |
Not clear |
| Correction to "Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program". Epilepsia. 2024-03-19. PMID:38502122. |
correction to "long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: four-year results from the expanded access program". |
2024-03-19 |
2024-03-21 |
Not clear |
| Giovanni Battista Dell'isola, Alberto Verrotti, Miriam Sciaccaluga, Gianluca Dini, Pietro Ferrara, Lucilla Parnetti, Cinzia Cost. Cannabidiol: metabolism and clinical efficacy in epileptic patients. Expert opinion on drug metabolism & toxicology. 2024-03-11. PMID:38465404. |
the landscape of epilepsy treatment has undergone a significant transformation with the emergence of cannabidiol as a potential therapeutic agent. |
2024-03-11 |
2024-03-14 |
Not clear |
| Correction to "Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program". Epilepsia. 2024-02-29. PMID:38420790. |
correction to "long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: four-year results from the expanded access program". |
2024-02-29 |
2024-03-02 |
Not clear |
| Ayushe A Sharma, Jerzy P Szaflarsk. The longitudinal effects of cannabidiol on brain temperature in patients with treatment-resistant epilepsy. Epilepsy & behavior : E&B. vol 151. 2024-01-10. PMID:38199054. |
the longitudinal effects of cannabidiol on brain temperature in patients with treatment-resistant epilepsy. |
2024-01-10 |
2024-01-13 |
human |
| Christopher Martínez-Aguirre, Luis Alfredo Márquez, Cindy Lizbeth Santiago-Castañeda, Francia Carmona-Cruz, Maria de Los Angeles Nuñez-Lumbreras, Vladimir A Martínez-Rojas, Mario Alonso-Vanegas, Gustavo Aguado-Carrillo, Norma L Gómez-Víquez, Emilio J Galván, Manola Cuéllar-Herrera, Luisa Roch. Cannabidiol Modifies the Glutamate Over-Release in Brain Tissue of Patients and Rats with Epilepsy: A Pilot Study. Biomedicines. vol 11. issue 12. 2023-12-23. PMID:38137458. |
cannabidiol modifies the glutamate over-release in brain tissue of patients and rats with epilepsy: a pilot study. |
2023-12-23 |
2023-12-25 |
rat |